Matrix metalloproteinases in arthritic disease
Citations Over TimeTop 10% of 2002 papers
Abstract
The role of matrix metalloproteinases in the degradative events invoked in the cartilage and bone of arthritic joints has long been appreciated and attempts at the development of proteinase inhibitors as potential therapeutic agents have been made. However, the spectrum of these enzymes orchestrating connective tissue turnover and general biology is much larger than anticipated. Biochemical studies of the individual members of the matrix metalloproteinase family are now underway, ultimately leading to a more detailed understanding of the function of their domain structures and to defining their specific role in cellular systems and the way that they are regulated. Coupled with a more comprehensive and detailed study of proteinase expression in different cells of joint tissues during the progress of arthritic diseases, it will be possible for the future development and application of highly specific proteinase inhibitors to be directed at specific key cellular events.
Related Papers
- → Membrane-type matrix metalloproteinases: Their functions and regulations(2015)425 cited
- Matrix Metalloproteinases(MMPs)and Tissue Inhibitors of Metalloproteinases(TIMPs)in the Development and Disease of Oral Tissues(1998)
- → Immunoexpression of matrix metalloproteinases MMP-1, MMP-2, MMP-9 and MMP-14 in extragenital endometriosis and eutopic endometrium(2020)2 cited
- → Changes of Serum Concentrations of Matrix Metalloproteinases,Tissue Inhibitors of Metalloproteinases and Type IV Collagen in patients with various types of glomerulonephritis(種々の糸球体腎炎患者におけるMatrix Metalloproteinases,Tissue Inhibitors of Metalloproteinases,IV型コラーゲンの血清中濃度の変化)(1997)